Xemilofiban

Xemilofiban is an orally active glycoprotein IIb/IIIa blocking agent. Xemilofiban inhibits platelet aggregation. Xemilofiban reduces the incidence of thrombosis[1][2].

Product Specifications

CAS Number

[149820-74-6]

UNSPSC

12352005

Target

Integrin

Related Pathways

Cytoskeleton

Field of Research

Cardiovascular Disease

Smiles

C#C[C@@H](NC(CCC(NC1=CC=C(C=C1)C(N)=N)=O)=O)CC(OCC)=O

Molecular Formula

C18H22N4O4

Molecular Weight

358.39

References & Citations

[1]Kereiakes DJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation. 1998 Sep 29;98 (13) :1268-78.|[2]Frederick LG, et al. Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin. Circulation. 1998 Aug 25;98 (8) :813-20.